Oramed Total Current Liabilities vs Net Receivables Analysis

ORMP Stock

USD 2.34 0.03 1.30%

Oramed Pharmaceuticals financial indicator trend analysis is much more than just breaking down Oramed Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Oramed Pharmaceuticals is a good investment. Please check the relationship between Oramed Pharmaceuticals Total Current Liabilities and its Net Receivables accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oramed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Oramed Stock, please use our How to Invest in Oramed Pharmaceuticals guide.

Total Current Liabilities vs Net Receivables

Total Current Liabilities vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Oramed Pharmaceuticals Total Current Liabilities account and Net Receivables. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Oramed Pharmaceuticals' Total Current Liabilities and Net Receivables is -0.18. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Oramed Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Oramed Pharmaceuticals' Total Current Liabilities and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Oramed Pharmaceuticals are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Total Current Liabilities i.e., Oramed Pharmaceuticals' Total Current Liabilities and Net Receivables go up and down completely randomly.

Correlation Coefficient

-0.18

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Total Current Liabilities

Total Current Liabilities is an item on Oramed Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Oramed Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Net Receivables

Most indicators from Oramed Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Oramed Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oramed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Oramed Stock, please use our How to Invest in Oramed Pharmaceuticals guide.At this time, Oramed Pharmaceuticals' Selling General Administrative is relatively stable compared to the past year. As of 11/24/2024, Enterprise Value is likely to grow to about 405.9 M, while Tax Provision is likely to drop 0.00.

	2020	2023	2024 (projected)
Gross Profit	2.6M	3.1M	1.9M
Total Revenue	2.7M	1.3M	2.0M

Gross Profit Total Revenue

Oramed Pharmaceuticals fundamental ratios Correlations

	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Common Stock	Total Assets	Net Debt	Accounts Payable	Cash	Cash And Short Term Investments	Non Current Liabilities Total	Other Current Assets	Total Current Assets	Short Long Term Debt Total	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other	Short Term Debt	Short Term Investments	Net Receivables	Inventory	Current Deferred Revenue	Capital Lease Obligations
Other Current Liab		-0.2	-0.46	0.32	-0.37	-0.39	-0.08	-0.39	-0.39	0.29	-0.52	-0.58	-0.41	0.43	-0.28	-0.42	-0.45	-0.44	-0.23	-0.58	-0.4	-0.25	0.02	0.19	0.05	-0.49
Total Current Liabilities	-0.2		0.79	-0.7	0.78	0.82	0.96	0.79	0.87	0.63	-0.02	0.03	0.84	0.03	0.0	0.8	0.82	0.74	0.92	-0.05	0.57	0.89	-0.18	-0.77	0.27	0.59
Total Stockholder Equity	-0.46	0.79		-0.93	0.97	0.99	0.77	0.97	0.99	0.1	0.48	0.53	0.99	0.03	0.29	0.99	0.96	0.98	0.8	0.28	0.69	0.91	-0.05	-0.72	0.33	0.94
Retained Earnings	0.32	-0.7	-0.93		-0.99	-0.97	-0.74	-0.98	-0.93	-0.02	-0.56	-0.54	-0.94	-0.28	-0.37	-0.95	-0.84	-0.9	-0.71	-0.23	-0.54	-0.86	-0.03	0.74	-0.57	-0.87
Common Stock Shares Outstanding	-0.37	0.78	0.97	-0.99		0.99	0.79	0.99	0.97	0.1	0.51	0.51	0.98	0.18	0.32	0.98	0.9	0.95	0.77	0.22	0.6	0.91	-0.01	-0.77	0.49	0.9
Other Stockholder Equity	-0.39	0.82	0.99	-0.97	0.99		0.82	0.99	0.99	0.15	0.46	0.49	0.99	0.13	0.3	0.99	0.94	0.96	0.82	0.22	0.64	0.93	-0.04	-0.77	0.43	0.91
Total Liab	-0.08	0.96	0.77	-0.74	0.79	0.82		0.8	0.86	0.59	0.07	0.04	0.82	0.3	0.0	0.78	0.76	0.69	0.93	-0.05	0.48	0.87	-0.11	-0.81	0.47	0.55
Common Stock	-0.39	0.79	0.97	-0.98	0.99	0.99	0.8		0.97	0.08	0.51	0.55	0.97	0.17	0.32	0.97	0.89	0.93	0.81	0.28	0.56	0.88	-0.03	-0.78	0.51	0.88
Total Assets	-0.39	0.87	0.99	-0.93	0.97	0.99	0.86	0.97		0.22	0.41	0.44	0.99	0.1	0.24	0.99	0.96	0.95	0.87	0.21	0.67	0.94	-0.06	-0.78	0.38	0.89
Net Debt	0.29	0.63	0.1	-0.02	0.1	0.15	0.59	0.08	0.22		-0.64	-0.76	0.21	-0.06	-0.37	0.15	0.23	0.09	0.4	-0.7	0.18	0.46	-0.22	-0.37	-0.18	-0.1
Accounts Payable	-0.52	-0.02	0.48	-0.56	0.51	0.46	0.07	0.51	0.41	-0.64		0.78	0.41	0.33	0.34	0.46	0.3	0.43	0.18	0.63	0.1	0.21	0.22	-0.36	0.51	0.55
Cash	-0.58	0.03	0.53	-0.54	0.51	0.49	0.04	0.55	0.44	-0.76	0.78		0.44	0.04	0.48	0.48	0.41	0.51	0.25	0.87	0.27	0.15	0.11	-0.15	0.39	0.63
Cash And Short Term Investments	-0.41	0.84	0.99	-0.94	0.98	0.99	0.82	0.97	0.99	0.21	0.41	0.44		0.06	0.27	1.0	0.97	0.98	0.81	0.17	0.69	0.95	-0.07	-0.75	0.34	0.92
Non Current Liabilities Total	0.43	0.03	0.03	-0.28	0.18	0.13	0.3	0.17	0.1	-0.06	0.33	0.04	0.06		-0.01	0.07	-0.1	-0.05	0.17	-0.01	-0.22	0.06	0.24	-0.29	0.82	-0.05
Other Current Assets	-0.28	0.0	0.29	-0.37	0.32	0.3	0.0	0.32	0.24	-0.37	0.34	0.48	0.27	-0.01		0.3	0.24	0.35	0.0	0.31	0.08	0.14	0.37	0.11	0.18	0.42
Total Current Assets	-0.42	0.8	0.99	-0.95	0.98	0.99	0.78	0.97	0.99	0.15	0.46	0.48	1.0	0.07	0.3		0.96	0.98	0.78	0.19	0.68	0.94	-0.05	-0.73	0.35	0.94
Short Long Term Debt Total	-0.45	0.82	0.96	-0.84	0.9	0.94	0.76	0.89	0.96	0.23	0.3	0.41	0.97	-0.1	0.24	0.96		0.98	0.78	0.17	0.83	0.93	-0.09	-0.62	0.17	0.93
Property Plant And Equipment Net	-0.44	0.74	0.98	-0.9	0.95	0.96	0.69	0.93	0.95	0.09	0.43	0.51	0.98	-0.05	0.35	0.98	0.98		0.71	0.21	0.75	0.91	-0.06	-0.62	0.23	0.98
Non Current Assets Total	-0.23	0.92	0.8	-0.71	0.77	0.82	0.93	0.81	0.87	0.4	0.18	0.25	0.81	0.17	0.0	0.78	0.78	0.71		0.25	0.5	0.78	-0.1	-0.78	0.42	0.59
Non Currrent Assets Other	-0.58	-0.05	0.28	-0.23	0.22	0.22	-0.05	0.28	0.21	-0.7	0.63	0.87	0.17	-0.01	0.31	0.19	0.17	0.21	0.25		0.07	-0.12	0.1	-0.03	0.33	0.31
Short Term Debt	-0.4	0.57	0.69	-0.54	0.6	0.64	0.48	0.56	0.67	0.18	0.1	0.27	0.69	-0.22	0.08	0.68	0.83	0.75	0.5	0.07		0.68	0.07	-0.26	-0.06	0.73
Short Term Investments	-0.25	0.89	0.91	-0.86	0.91	0.93	0.87	0.88	0.94	0.46	0.21	0.15	0.95	0.06	0.14	0.94	0.93	0.91	0.78	-0.12	0.68		-0.1	-0.77	0.24	0.81
Net Receivables	0.02	-0.18	-0.05	-0.03	-0.01	-0.04	-0.11	-0.03	-0.06	-0.22	0.22	0.11	-0.07	0.24	0.37	-0.05	-0.09	-0.06	-0.1	0.1	0.07	-0.1		0.08	0.2	-0.02
Inventory	0.19	-0.77	-0.72	0.74	-0.77	-0.77	-0.81	-0.78	-0.78	-0.37	-0.36	-0.15	-0.75	-0.29	0.11	-0.73	-0.62	-0.62	-0.78	-0.03	-0.26	-0.77	0.08		-0.5	-0.51
Current Deferred Revenue	0.05	0.27	0.33	-0.57	0.49	0.43	0.47	0.51	0.38	-0.18	0.51	0.39	0.34	0.82	0.18	0.35	0.17	0.23	0.42	0.33	-0.06	0.24	0.2	-0.5		0.19
Capital Lease Obligations	-0.49	0.59	0.94	-0.87	0.9	0.91	0.55	0.88	0.89	-0.1	0.55	0.63	0.92	-0.05	0.42	0.94	0.93	0.98	0.59	0.31	0.73	0.81	-0.02	-0.51	0.19

Click cells to compare fundamentals

Oramed Pharmaceuticals Account Relationship Matchups

Oramed Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	(69K)	601K	(1.4M)	(191K)	(171.9K)	(163.3K)
Total Current Liabilities	5.3M	4.5M	6.7M	5.7M	53.2M	55.9M
Total Stockholder Equity	19.4M	32.9M	115.8M	151.8M	163.8M	172.0M
Retained Earnings	(81.1M)	(92.6M)	(114.9M)	(163.1M)	(157.6M)	(149.7M)
Common Stock Shares Outstanding	17.5M	20.5M	28.5M	39.0M	40.3M	42.4M
Other Stockholder Equity	100.3M	125.2M	230.2M	314.4M	361.6M	379.7M
Total Liab	15.3M	11.8M	11.5M	10.5M	57.7M	60.5M
Common Stock	208K	284K	424K	476K	547.4K	574.8K
Total Assets	34.7M	44.6M	128.0M	161.6M	220.6M	231.6M
Net Debt	(3.3M)	(19.2M)	(76.7M)	(39.6M)	42.0M	44.1M
Accounts Payable	1.3M	594K	2.6M	2.2M	551K	822.2K
Cash	3.3M	19.3M	77.2M	40.5M	9.1M	10.6M
Cash And Short Term Investments	32.3M	39.9M	94.1M	155.7M	179.1M	188.0M
Liabilities And Stockholders Equity	34.7M	44.6M	128.0M	161.6M	185.9M	195.2M
Non Current Liabilities Total	10.0M	7.2M	4.8M	4.7M	4.4M	4.2M
Other Current Assets	1.0M	611K	1.2M	1.4M	537K	536.1K
Total Current Assets	33.3M	40.5M	95.3M	157.1M	162.6M	170.7M
Property Plant And Equipment Net	24K	174K	932K	1.8M	1.6M	1.6M
Non Current Assets Total	1.3M	4.1M	32.7M	4.5M	58.0M	60.9M
Short Term Investments	29.0M	20.6M	16.9M	115.3M	153.0M	160.6M

Pair Trading with Oramed Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oramed Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oramed Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Oramed Stock

0.66

23Andme Holding

Pair Corr

Moving against Oramed Stock

0.62	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.48	GILD	Gilead Sciences	Pair Corr
0.47	EWTX	Edgewise Therapeutics	Pair Corr

The ability to find closely correlated positions to Oramed Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oramed Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oramed Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oramed Pharmaceuticals to buy it.

The correlation of Oramed Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oramed Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oramed Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Oramed Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Oramed Stock Analysis

When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC